Wall Street brokerages forecast that Intersect ENT Inc (NASDAQ:XENT) will announce earnings per share (EPS) of ($0.23) for the current fiscal quarter, Zacks reports. Nine analysts have provided estimates for Intersect ENT’s earnings, with the lowest EPS estimate coming in at ($0.32) and the highest estimate coming in at ($0.12). Intersect ENT also reported earnings of ($0.23) per share during the same quarter last year. The business is scheduled to report its next quarterly earnings results on Tuesday, May 1st.
On average, analysts expect that Intersect ENT will report full-year earnings of ($0.59) per share for the current fiscal year, with EPS estimates ranging from ($0.75) to ($0.24). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.18) per share, with EPS estimates ranging from ($0.45) to $0.43. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Intersect ENT.
Intersect ENT (NASDAQ:XENT) last announced its earnings results on Tuesday, February 27th. The medical equipment provider reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.06. Intersect ENT had a negative net margin of 16.99% and a negative return on equity of 14.40%. The firm had revenue of $29.53 million for the quarter, compared to the consensus estimate of $29.45 million.
Shares of Intersect ENT (NASDAQ XENT) opened at $38.90 on Friday. Intersect ENT has a 52 week low of $14.60 and a 52 week high of $39.00.
In related news, CFO Jeryl L. Hilleman sold 12,833 shares of the stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $35.92, for a total value of $460,961.36. Following the transaction, the chief financial officer now directly owns 36,265 shares of the company’s stock, valued at approximately $1,302,638.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Richard E. Kaufman sold 958 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $37.21, for a total transaction of $35,647.18. Following the completion of the transaction, the chief operating officer now directly owns 87,512 shares in the company, valued at $3,256,321.52. The disclosure for this sale can be found here. Over the last three months, insiders sold 136,310 shares of company stock worth $4,660,238. Insiders own 13.70% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Jennison Associates LLC grew its position in shares of Intersect ENT by 22.4% in the 4th quarter. Jennison Associates LLC now owns 2,036,202 shares of the medical equipment provider’s stock valued at $65,973,000 after buying an additional 372,320 shares during the last quarter. BlackRock Inc. grew its position in shares of Intersect ENT by 2.0% in the 4th quarter. BlackRock Inc. now owns 1,980,942 shares of the medical equipment provider’s stock valued at $64,183,000 after buying an additional 39,761 shares during the last quarter. Alliancebernstein L.P. grew its position in shares of Intersect ENT by 12.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,466,730 shares of the medical equipment provider’s stock valued at $47,522,000 after buying an additional 161,723 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Intersect ENT by 6.7% in the 2nd quarter. Vanguard Group Inc. now owns 1,139,623 shares of the medical equipment provider’s stock valued at $31,853,000 after buying an additional 71,750 shares during the last quarter. Finally, Neuberger Berman Group LLC boosted its stake in Intersect ENT by 8.0% during the 3rd quarter. Neuberger Berman Group LLC now owns 802,521 shares of the medical equipment provider’s stock worth $24,999,000 after purchasing an additional 59,620 shares during the period. 84.49% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Zacks: Analysts Expect Intersect ENT Inc (XENT) to Announce -$0.23 EPS” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://sportsperspectives.com/2018/03/13/zacks-analysts-expect-intersect-ent-inc-xent-to-announce-0-23-eps.html.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.